FindTrial
Sign In

Prospective Clinical Study on Juhe Xiaotong Yin in the Treatment of Hyperuricemia

Prospective Clinical Study on Juhe Xiaotong Yin in the Treatment of Hyperuricemia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001004
Enrollment
Unknown
Registered
2026-04-16
Start date
2026-05-01
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricemia

Interventions

Experimental Group:Juhe Xiaotong Yin
Control Group:Febuxostat

Sponsors

Guangdong Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age =18 and =70 years, regardless of gender; 2. Persistent elevation of serum uric acid (SUA) during screening period meeting hyperuricemia criteria: SUA =428µmol/L and =540µmol/L; 3. Voluntarily sign informed consent and cooperate with follow-up examinations; 4. Able to comply with study requirements with good adherence (no use of prohibited medications during study period).

Exclusion criteria

Exclusion criteria: 1. Secondary gout (caused by tumors, renal insufficiency, etc.) 2. eGFR 2×ULN 4. Severe cardiovascular/cerebrovascular diseases 5. Pregnant or lactating women 6. Allergy to febuxostat or any component of the formula 7. Participation in other clinical trials 8. Current use of theophylline, mercaptopurine or azathioprine

Design outcomes

Primary

MeasureTime frame
Serum uric acid;—

Secondary

MeasureTime frame
crp;esr;Traditional Chinese Medicine Syndrome Scoring Scale;TCM Syndrome Differentiation Scale;—

Countries

China

Contacts

Public ContactHuang Ziyi

Guangzhou University of Traditional Chinese Medicine

galahadhwung@outlook.com18023452584

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026